Bank of America
AGRX

Bank of America’s Agile Therapeutics AGRX Stock Holding History

Bank of America’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Hold
0
– – – 8661
2022
Q1 		– Hold
0
– – – 9012
2021
Q4 		– Sell
-4
Closed -$6K – 8869
2021
Q3 		$6K Sell
4
-1
-20% -$2.26K ﹤0.01% 7711
2021
Q2 		$15K Sell
5
-25
-83% -$82.4K ﹤0.01% 7223
2021
Q1 		$126K Buy
30
+23
+329% +$124K ﹤0.01% 6293
2020
Q4 		$39K Buy
7
+4
+133% +$23.5K ﹤0.01% 6417
2020
Q3 		$19K Sell
3
-10
-77% -$57.3K ﹤0.01% 6303
2020
Q2 		$72K Sell
13
-20
-61% -$104K ﹤0.01% 5823
2020
Q1 		$125K Buy
+33
New +$189K ﹤0.01% 5398
2017
Q3 		– Sell
-3
Closed -$19K – 7354
2017
Q2 		$19K Sell
3
-1
-25% -$6.92K ﹤0.01% 6244
2017
Q1 		$23K Buy
4
+3
+300% +$15.1K ﹤0.01% 6266
2016
Q4 		$10K Buy
+1
New +$14K ﹤0.01% 6560
2016
Q3 		– Hold
0
– – – 6564
2016
Q2 		– Hold
0
– – – 6835
2016
Q1 		– Hold
0
– -$2K – 7426
2015
Q4 		– Hold
0
– – – 7122
2015
Q3 		– Hold
0
– – – 7070
2015
Q2 		– Hold
0
– – – 7065

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of America's AGRX Position: Q2 2022 in Review

Bank of America held its Agile Therapeutics (AGRX) position steady in Q2 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #8661.

Bank of America first reported a position in AGRX in Q4 2016 and has held it in 10 quarters since. The position peaked at $126K in Q1 2021. 19 funds tracked by Wall St. Rank hold AGRX as of Q2 2022.

  • Bank of America held 0 shares of Agile Therapeutics worth $0 as of Q2 2022.
  • Bank of America left its Agile Therapeutics share count unchanged in Q2 2022.
  • Agile Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2022, its #8661 holding.
  • Bank of America first reported a position in Agile Therapeutics in Q4 2016 and has held it in 10 quarters since.
  • Bank of America's Agile Therapeutics position peaked at $126K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2022.

Based on Bank of America's 13F filing for Q2 2022, filed 12 Aug 2022.